<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1168290" disease_type="Disease or Syndrome" abbrv="">Drug-induced hypersensitivity syndrome</z:e> is a <z:e sem="disease" ids="C0521465" disease_type="Disease or Syndrome" abbrv="">toxicoderma</z:e> with systemic involvement </plain></SENT>
<SENT sid="1" pm="."><plain>Suspicion of this disorder obliges rapid withdrawal of the suspected drug, which may have been introduced up to 3 months earlier </plain></SENT>
<SENT sid="2" pm="."><plain>Screening for human herpesvirus (HHV) 6 reactivation is important both for its diagnostic value and for its association with a poor prognosis </plain></SENT>
<SENT sid="3" pm="."><plain>Reactivation of this virus is not a contraindication for systemic <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> treatment, which should be tapered slowly in order to avoid recurrence </plain></SENT>
<SENT sid="4" pm="."><plain>The possible appearance of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> must also be considered in those cases associated with <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, altered hemostasis, or thrombotic events </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002960'>Autoimmune disorders</z:hpo> may also develop as a sequela of the condition </plain></SENT>
<SENT sid="6" pm="."><plain>Medium-to-long-term follow-up is required even after complete resolution of the condition </plain></SENT>
<SENT sid="7" pm="."><plain>We describe a new case of <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi>-induced <z:e sem="disease" ids="C0543698" disease_type="Disease or Syndrome" abbrv="">hypersensitivity syndrome</z:e> associated with HHV-6 reactivation and the induction of anticardiolipin and anti-thyroid peroxidase antibodies </plain></SENT>
</text></document>